Breast Cancer
Research results from M. Theodoulou and co-authors update knowledge of breast cancer
Published in Cancer Weekly, June 23rd, 2009
"This was an open-label, nonrandomized, multicenter, 2-stage phase I trial of safety and preliminary efficacy of nonpegylated liposomal doxorubicin (NLD) in combination with trastuzumab in advanced breast cancer, with emphasis on cardiac toxicity. Forty patients (median age, 48 years; range, 30-74 years) with HER2/neu 2+ or 3+ tumors (by immunohistochemistry) were recruited December 1999 to November 2002," scientists in the United States report.
"Patients were eligible if they received <= 1 previous trastuzurnab regimen, <= 2 cytotoxic regimens for advanced breast cancer, and lifetime cumulative anthracycline doses <= 240 mg/m(2). The study regimen comprised...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2009-06-23)
More Articles from Cancer Weekly
- Cancer Gene Therapy
Findings in cancer gene therapy reported from University of Pennsylvania, Medical Department - Cancer Gene Therapy
New cancer gene therapy research from A. Azatian and colleagues discussed - Cancer Gene Therapy
Report summarizes cancer gene therapy study findings from Hokkaido University, Medical Department - Cancer Gene Therapy
Research on cancer gene therapy reported by E. Kuwada et al - Cancer Vaccines
Data on cancer vaccines published by researchers at National Cancer Institute - Cancer Vaccines
New cancer vaccines study findings recently were published by researchers at University of California - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
